AU762211B2 - Identifying material from a breast duct - Google Patents

Identifying material from a breast duct Download PDF

Info

Publication number
AU762211B2
AU762211B2 AU57679/01A AU5767901A AU762211B2 AU 762211 B2 AU762211 B2 AU 762211B2 AU 57679/01 A AU57679/01 A AU 57679/01A AU 5767901 A AU5767901 A AU 5767901A AU 762211 B2 AU762211 B2 AU 762211B2
Authority
AU
Australia
Prior art keywords
ductal
protein
breast
duct
marker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU57679/01A
Other languages
English (en)
Other versions
AU5767901A (en
Inventor
David Hung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atossa Therapeutics Inc
Original Assignee
Pro Duct Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pro Duct Health Inc filed Critical Pro Duct Health Inc
Publication of AU5767901A publication Critical patent/AU5767901A/en
Application granted granted Critical
Publication of AU762211B2 publication Critical patent/AU762211B2/en
Assigned to CYTYC HEALTH CORPORATION reassignment CYTYC HEALTH CORPORATION Alteration of Name(s) of Applicant(s) under S113 Assignors: PRO DUCT HEALTH, INC.
Assigned to CYTYC CORPORATION reassignment CYTYC CORPORATION Alteration of Name(s) in Register under S187 Assignors: CYTYC HEALTH CORPORATION
Assigned to CYTYC CORPORATION reassignment CYTYC CORPORATION Alteration of Name(s) in Register under S187 Assignors: CYTYC CORPORATION
Assigned to ATOSSA GENETICS, INC. reassignment ATOSSA GENETICS, INC. Alteration of Name(s) in Register under S187 Assignors: CYTYC CORPORATION
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M3/00—Medical syringes, e.g. enemata; Irrigators
    • A61M3/02—Enemata; Irrigators
    • A61M3/0233—Enemata; Irrigators characterised by liquid supply means, e.g. from pressurised reservoirs
    • A61M3/0254—Enemata; Irrigators characterised by liquid supply means, e.g. from pressurised reservoirs the liquid being pumped
    • A61M3/0262—Enemata; Irrigators characterised by liquid supply means, e.g. from pressurised reservoirs the liquid being pumped manually, e.g. by squeezing a bulb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M3/00—Medical syringes, e.g. enemata; Irrigators
    • A61M3/02—Enemata; Irrigators
    • A61M3/0279—Cannula; Nozzles; Tips; their connection means
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B10/00—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
    • A61B10/0041—Detection of breast cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/10—Trunk
    • A61M2210/1007—Breast; mammary

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
AU57679/01A 2000-07-26 2001-07-26 Identifying material from a breast duct Ceased AU762211B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/625399 2000-07-26
US09/625,399 US6610484B1 (en) 1999-01-26 2000-07-26 Identifying material from a breast duct

Publications (2)

Publication Number Publication Date
AU5767901A AU5767901A (en) 2002-01-31
AU762211B2 true AU762211B2 (en) 2003-06-19

Family

ID=24505894

Family Applications (1)

Application Number Title Priority Date Filing Date
AU57679/01A Ceased AU762211B2 (en) 2000-07-26 2001-07-26 Identifying material from a breast duct

Country Status (6)

Country Link
US (4) US6610484B1 (https=)
EP (1) EP1182459A3 (https=)
JP (1) JP2002131322A (https=)
AU (1) AU762211B2 (https=)
CA (1) CA2353193A1 (https=)
IL (1) IL144514A0 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020110609A1 (en) * 1998-12-28 2002-08-15 David Hung Increasing retrievable fluid from a breast duct
US6413228B1 (en) * 1998-12-28 2002-07-02 Pro Duct Health, Inc. Devices, methods and systems for collecting material from a breast duct
US6638727B1 (en) * 1999-01-26 2003-10-28 Cytyc Health Corporation Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
CA2370539C (en) 1999-04-23 2009-01-06 Massachusetts Institute Of Technology System and method for notating polymers
US6642009B2 (en) 1999-05-17 2003-11-04 Cytyc Health Corporation Isolated ductal fluid sample
US20040153001A1 (en) * 1999-12-28 2004-08-05 David Hung Devices, methods and systems for collecting material from a breast duct
US20080194022A1 (en) * 2000-08-03 2008-08-14 Clarke Michael F Isolation and use of solid tumor stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US6984522B2 (en) * 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
WO2002031507A2 (en) * 2000-10-13 2002-04-18 Children's Medical Center Corporation Non-invasive enzyme screen for tissue remodelling-associated conditions
US6866994B2 (en) * 2001-05-30 2005-03-15 Neomatrix, Llc Noninvasive intraductal fluid diagnostic screen
JP2004532082A (ja) * 2001-05-30 2004-10-21 ネオマトリックス・エルエルシー 非侵襲性管内流体診断スクリーン
US20040137539A1 (en) * 2003-01-10 2004-07-15 Bradford Sherry A. Cancer comprehensive method for identifying cancer protein patterns and determination of cancer treatment strategies
US7666583B2 (en) 2004-02-19 2010-02-23 Yale University Identification of cancer protein biomarkers using proteomic techniques
US20060127950A1 (en) * 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
US20060057638A1 (en) * 2004-04-15 2006-03-16 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
US20070243540A1 (en) * 2004-05-21 2007-10-18 Tsai Jo C Kits and Methods for Identification, Assessment, Prevention and Therapy of Breast Cancer
EP1907858A4 (en) * 2005-06-13 2009-04-08 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
CA2628091A1 (en) * 2005-11-02 2007-05-18 Bayer Healthcare Llc Methods for prediction and prognosis of cancer, and monitoring cancer therapy
CN101351709A (zh) * 2005-11-02 2009-01-21 拜尔健康护理有限责任公司 癌症的预测和预后以及监控癌症治疗的方法
CN101379400A (zh) * 2005-12-22 2009-03-04 诺华有限公司 可溶性人m-csf受体及其应用
WO2007098102A2 (en) * 2006-02-17 2007-08-30 Children's Medical Center Corporation Free ngal as a biomarker for cancer
EP3796002B1 (en) * 2006-07-14 2023-11-22 The Regents of The University of California Cancer biomarkers and methods of use thereof
KR20090071603A (ko) * 2006-09-19 2009-07-01 노파르티스 아게 Ｒａｆ 억제제에 대한 표적 조절, 효능, 진단 및/또는 예후의 바이오마커
WO2008092002A2 (en) 2007-01-24 2008-07-31 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
EP2161577A1 (en) * 2008-09-01 2010-03-10 Atlas Antibodies AB ANLN protein
WO2010041423A1 (ja) * 2008-10-09 2010-04-15 日本電気株式会社 病理組織診断支援システム、病理組織診断支援プログラム、病理組織診断支援方法
US20100136579A1 (en) * 2008-12-02 2010-06-03 Industrial Technology Research Institute Biomarkers useful in liver fibrosis diagnosis
WO2010118324A2 (en) 2009-04-09 2010-10-14 Nuclea Biotechnologies, LLC Antibodies against fatty acid synthase
JP5387146B2 (ja) * 2009-06-03 2014-01-15 日本電気株式会社 病理組織画像解析装置、病理組織画像解析方法、病理組織画像解析プログラム
WO2011031517A1 (en) 2009-08-27 2011-03-17 Nuclea Biotechnologies, LLC Method and assay for determining fas expression
WO2011139721A1 (en) 2010-04-27 2011-11-10 The Regents Of The University Of California Cancer biomarkers and methods of use thereof
WO2014038524A1 (ja) 2012-09-05 2014-03-13 和光純薬工業株式会社 乳癌の判定方法
EP2963420A1 (en) 2013-02-26 2016-01-06 Wako Pure Chemical Industries, Ltd. Breast-cancer determination method
WO2016090323A1 (en) 2014-12-05 2016-06-09 Prelude, Inc. Dcis recurrence and invasive breast cancer
US10151001B2 (en) 2014-12-29 2018-12-11 National Guard Health Affairs Quantification of Lamin C and Lamin A for tumor classification
EP3414394B1 (en) * 2016-02-08 2023-09-13 GPCP IP Holdings LLC Molding roll for making paper products
WO2020056338A1 (en) 2018-09-14 2020-03-19 Prelude Corporation Method of selection for treatment of subjects at risk of invasive breast cancer
WO2020220136A1 (en) * 2019-05-02 2020-11-05 The Hospital For Sick Children Detection of biomarkers associated with brugada syndrome
CN111521312A (zh) * 2020-05-08 2020-08-11 中国工程物理研究院化工材料研究所 一种基于盲孔法标定光纤测量材料残余应力的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999013917A1 (en) * 1997-09-16 1999-03-25 The Regents Of The University Of California Methods and kits for identifying ductal orifices in a nipple
WO1999055384A1 (en) * 1998-04-28 1999-11-04 The Regents Of The University Of California Method and kit for obtaining fluids and cellular material from breast ducts
WO2000070349A1 (en) * 1999-05-17 2000-11-23 Pro Duct Health, Inc. Identifying material from a breast duct

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4782015A (en) 1984-03-30 1988-11-01 Syntex (U.S.A.) Inc. Method for determining the presence of malignant cells
EP0319686A3 (en) 1987-10-21 1991-04-24 Mochida Pharmaceutical Co., Ltd. Method for assaying a target substance in a minute amount of nipple discharge and device for such an assay
EP0636248A4 (en) 1992-04-14 1996-11-13 Univ Duke METHOD FOR DETECTING P53 AND HSP70 COMPLEX CONTAINING TUMORS.
US5478556A (en) 1994-02-28 1995-12-26 Elliott; Robert L. Vaccination of cancer patients using tumor-associated antigens mixed with interleukin-2 and granulocyte-macrophage colony stimulating factor
WO1997005898A1 (en) 1995-08-03 1997-02-20 The Johns Hopkins University School Of Medicine Delivery of an agent to the ductal epithelium in the prophylactic and therapeutic treatment of cancer
US5763415A (en) 1995-08-03 1998-06-09 John Hopkins University School Of Medicine Destruction of the epithelium of an exocrine gland in the prophylactic and therapeutic treatment of cancer
US5914238A (en) 1996-06-05 1999-06-22 Matritech, Inc. Materials and methods for detection of breast cancer
US5798266A (en) 1996-08-27 1998-08-25 K-Quay Enterprises, Llc Methods and kits for obtaining and assaying mammary fluid samples for breast diseases, including cancer
US6046929A (en) * 1998-04-06 2000-04-04 Fujitsu Limited Memory device with two ferroelectric capacitors per one cell
US6287790B1 (en) * 1998-11-30 2001-09-11 The Regents Of The University Of California Utilization of nuclear structural proteins for targeted therapy and detection of proliferative and differentiation disorders
JP4667594B2 (ja) * 2000-12-25 2011-04-13 ルネサスエレクトロニクス株式会社 薄膜磁性体記憶装置

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999013917A1 (en) * 1997-09-16 1999-03-25 The Regents Of The University Of California Methods and kits for identifying ductal orifices in a nipple
WO1999055384A1 (en) * 1998-04-28 1999-11-04 The Regents Of The University Of California Method and kit for obtaining fluids and cellular material from breast ducts
WO2000070349A1 (en) * 1999-05-17 2000-11-23 Pro Duct Health, Inc. Identifying material from a breast duct

Also Published As

Publication number Publication date
US20120034644A1 (en) 2012-02-09
EP1182459A2 (en) 2002-02-27
IL144514A0 (en) 2002-05-23
EP1182459A3 (en) 2003-01-08
US20130078650A1 (en) 2013-03-28
JP2002131322A (ja) 2002-05-09
CA2353193A1 (en) 2002-01-26
US20040018546A1 (en) 2004-01-29
AU5767901A (en) 2002-01-31
US6610484B1 (en) 2003-08-26

Similar Documents

Publication Publication Date Title
AU762211B2 (en) Identifying material from a breast duct
AU764777B2 (en) Methods for identifying, treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
US6413228B1 (en) Devices, methods and systems for collecting material from a breast duct
AU2002237838B2 (en) Isolated ductal fluid sample
Ellenson et al. 8 Precursor Lesions of Endometrial
EP1179184B1 (en) Identifying material from a breast duct
AU762512B2 (en) Devices, methods and systems for collecting material from a breast duct
IL146374A (en) Method for identifying a patient having breast cancer
US20070270708A1 (en) Devices, methods and systems for collecting material from a breast duct
Ueyama et al. Ileal adenomyoma accompanied by primary peritonitis: report of a case
AU2008202312A1 (en) Isolated ductal fluid sample

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: CYTYC HEALTH CORPORATION

Free format text: THE FORMER OWNER WAS: PRO DUCT HEALTH, INC

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: CYTYC CORPORATION

Free format text: FORMER OWNER WAS: CYTYC HEALTH CORPORATION

PC Assignment registered

Owner name: CYTYC CORPORATION

Free format text: FORMER OWNER WAS: CYTYC CORPORATION